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Abstract
Background: CPAP titration may be completed by automatic apparatus. However, differences in
pressure behaviour could interfere with the reliability of pressure recommendations. Our objective
was to compare pressure behaviour and effective pressure recommendations between three
Automatic CPAP machines (Autoset Spirit, Remstar Auto, GK 420).
Methods: Sixteen untreated obstructive sleep apnea patients were randomly allocated to one of
the 3 tested machines for a one-week home titration trial in a crossover design with a 10 days
washout period between trials.
Results: The median pressure value was significantly lower with machine GK 420 (5.9 +/- 1.8 cm
H2O) than with the other devices both after one night and one week of CPAP titration (7.4 +/- 1.3
and 6.6 +/- 1.9 cm H2O). The maximal pressure obtained over the one-week titration was
significantly higher with Remstar Auto (12.6 +/- 2.4 cm H2O, Mean +/- SD) than with the two other
ones (10.9 +/- 1.0 and 11.0 +/- 2.4 cm H2O). The variance in pressure recommendation significantly
differed between the three machines after one night and between Autoset Spirit and the two other
machines after 1 week.
Conclusion: Pressure behaviour and pressure recommendation significantly differ between Auto
CPAP machines both after one night and one week of home titration.
Background
Obstructive sleep apnea hypopnea syndrome (OSAHS) is
highly prevalent in the middle age active population [1,2].
The consequences of obstructive breathing disturbances
on sleep structure and continuity, tissue oxygenation,
hemodynamic variables and on the release of systemic
inflammatory mediators can account for vigilance and
quality of life impairments [3] as well as for the increase
in morbidity and mortality [4-7]. Nasal continuous posi-
tive airway pressure (CPAP) represents a very effective
treatment for OSAHS as demonstrated by the results of
different randomized controlled [8-11] and non-rand-
omized trials [12].
The effective pressure level (Peff) is the one that abolishes
obstructive breathing disorders including inspiratory flow
limitation and snoring in every sleep stage and body posi-
tion [13]. It is usually determined during an in-laboratory
titration sleep study with continuous acquisition of elec-
trophysiologic variables, instantaneous respiratory flow,
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respiratory efforts and pulse oximetry. Automatic CPAP
devices have been developed that continuously adapt the
applied pressure level to the ventilatory profile [14]. These
devices may be used in two different ways, one is to
replace the in-laboratory titration sleep study and deter-
mine the Peff level in the patient's usual sleeping environ-
ment. These automatic titration procedures have been
widely used in the literature [8,10,11] and can be used in
clinical practice in the management of CPAP therapy
[15,16]. Then when completing an automatic CPAP titra-
tion, Peff value usually corresponds to the 90th or 95th per-
centile of the cumulative night time pressure response.
The other application of auto CPAP therapy is to simply
replace conventional fixed CPAP therapy at home by a
machine that should automatically modify the pressure
setting accounting for intra night and night-to-night
changes in Peff [17].
Different automatic CPAP devices are presently available
that differ in the analyzed signals, in the definition of res-
piratory events, in the signal processing as well as in the
algorithm of pressure response [18-24]. This results in sig-
nificant differences in the positive pressure behaviour in
response to bench-simulated [25,26] or naturally occur-
ring sleep-induced breathing disturbances [27]. One
should expect such specificity in the machine pressure
response to influence the amount and duration of pres-
sure changes and consecutively the pressure recommenda-
tion between different automatic CPAP machines. This
has been found to be the case when comparing in-labora-
tory [28] as well as home [29] titration results with two
Auto CPAP devices (Autoset, Resmed, Sydney Australia
and Somnosmart, Weinmann, Hamburg, Germany)
whose response algorithms are based on entirely different
physiologic principles (i.e. correction of apnea/hypopnea
and flow/time profile vs. maintenance of respiratory sys-
tem impedance below awake values while asleep respec-
tively). Nolan recently reported that pressure delivery
significantly differs between machines using different
algorithms of pressure response that are driven by respira-
tory flow analysis [30], but the impact of such differences
on positive pressure setting cannot be drawn from this last
study since it was conducted in patients previously treated
with CPAP with no aim to establish and compare positive
pressure recommendations.
The aims of the present study were to compare pressure
behaviour and Peff recommendations between three dif-
ferent Automatic CPAP machines and evaluate if these
parameters are influenced by titration duration.
Methods
Sixteen newly diagnosed consecutive subjects participated
in the study. The diagnosis of sleep apnea was made
according to clinical symptoms and to the results of
ambulatory (oxygen desaturation index > 15/h, n = 8) or
in-laboratory sleep recordings (AHI > 10/h, n = 8). These
nocturnal recordings were scored according to recommen-
dations of the literature [31,32]. Patients selected CPAP as
their treatment choice after discussion of other treatment
alternatives. No patient had ever been treated for OSAHS.
Their weight had to be stable over the last 2 months with
no change in medication during this period. They were
asked not to initiate a weight loss strategy before the end
of the study. Patients should have normal nasal ventila-
tion and no documented obstructive or restrictive lung
disease, neuromuscular disorder or congestive heart fail-
ure. They should not be taking any CNS/respiratory
depressant medication and alcohol consumption had to
be less than 0.5 g alcohol/Kg per day. Patients whose diur-
nal somnolence represented an urgent indication for
treatment according to the referring pneumologist were
not eligible to participate. The ethical review board
approved the protocol and subjects provided informed
written consent.
Study design
An experienced sleep technologist who also explained to
patients the functioning of Auto CPAP devices made the
cautious choice of the nasal mask. Patients were randomly
allocated to one of the investigated Auto CPAP machines
(GK 420 – Tyco Healthcare International, AutoSet Spirit –
ResMed, Sydney Australia, Remstar Auto – Respironics,
Murrysville, PA) for a one-week home titration trial in a
crossover design with a 10 days washout period between
trials. Each machine was used with default settings with
lower and upper pressure bounds set to 4 and 16 cm H2O
respectively. Anthropomorphic characteristics were meas-
ured at the beginning of each trial. At the end of each treat-
ment session, information recorded by the Auto CPAP
device was downloaded to determine adherence to treat-
ment, to measure apnea + hypopnea index and leaks level,
applied pressure range, median pressure value, and
default values of the recommended Peff level (90th percen-
tile pressure levels for GK 420 and RemStar Auto and 95th
for AutoSet Spirit). These parameters were determined
separately for the first night and the whole week of treat-
ment.
Statistical analysis
The sample size was determined according to the results
of a pilot study conducted in 8 subjects to observe a 90%
chance of showing a 2 cm H2O statistical difference in the
recommended pressure level between the 3 tested
machines with a two-sided significant level of 5%. The
results obtained in these 8 subjects are not part of the
present results. For the one night and one-week recording
sessions, analyzed variables obtained from machines'
reports were CPAP compliance, AHI, pressure characteris-
tics (maximum, minimum, median and recommendedRespiratory Research 2008, 9:56 http://respiratory-research.com/content/9/1/56
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effective pressure levels). Data recorded on "night 1" were
analysed using a randomized block design (mixed
model). Subjects were linked to the block effect (random
effect) and machines (Autoset Spirit, GK-420 and RemStar
Auto) were associated to the fixed effect. The Tukey's
adjustment was used to perform posteriori multiple com-
parisons. The same statistical approach was used for meas-
urement over the week recording. To compare night1 and
one-week recordings, a second fixed factor was added to
the previous statistical model with an interaction effect
with machines. The univariate and multivariate normality
assumption were verified with the Shapiro-Wilk and Mar-
dia's tests respectively. The results were considered signif-
icant with p-values ≤ 0.05. The data were analyzed using
the statistical package program SAS v 9.1.3 (SAS Institute
Inc.).
Results
The characteristics of participating patients are reported in
Table 1. Symptoms, co-morbidities and anthropometric
variables did not differ between patients whose diagnosis
was confirmed with ambulatory or in-laboratory sleep
recording. Anthropometric variables remained
unchanged at the different visits. No change in mask was
required within the different titration sessions or from
one session to the other. No subject complained of any
symptom of nasal obstruction during the course of the
study. No data loss occurred except in one patient who
repeatedly turned the machine on and off during the first
night of the last treatment session with Remstar Auto.
CPAP usage was similar between the three machines
(table 2 and 3). The apnea + hypopnea index (AHI)
remained greater than 10/h in 2/16 subjects during the
first night titration with Remstar Auto and in 2 other sub-
jects during the one week titration (one with Remstar
Auto and GK 420). AHI values significantly differed
between the 3 devices both after one night and one week
of titration (Table 2 and 3). Leaks remained in the normal
value range in each subject (less than 0.4 L/min with
Autoset Spirit, less than the maximal computed leak level
with GK-420 and without periods of "large leaks" indi-
cated by the RemStar Auto). The maximal pressure
reached did not differ between the three Auto CPAP
devices for the first night but its variance was significantly
higher with GK-420 (10.7) than Autoset Spirit and Rem-
Star Auto (1.64 and 5.47 respectively, p < 0.05). The max-
imal pressure obtained over the one-week titration was
significantly higher with the RemStar Auto than with the
two other ones (Table 2 and 3). Furthermore, the maximal
pressure variance of the one-week recording was signifi-
cantly higher for RemStar Auto and GK-420 (4.31 and
5.71 respectively) than Autoset Spirit (1.22) (p < 0.05).
The minimal pressure level reached 4 cm H2O with the
three devices for each titration duration. The median pres-
sure value was significantly lower with GK-420 than with
the other devices both after one night and one week of
CPAP titration (Table 2 and 3). Furthermore, the median
pressure variance measured at one week was borderline
significant between the 3 machines (Autoset Spirit: 1.86,
RemStar Auto: 3.31, GK-420: 3.01, 0.05 < p <0.1). The dif-
ference in median pressure values measured overtime was
significantly less for GK-420 than for the two other
machines (p = 0.003). The intra-night pressure variability
was estimated by the difference between the effective and
Table 2: Results of the titration studies according to each Auto CPAP device during the first titration night.
Auto CPAP device Autoset Spirit Remstar Auto GK 420
CPAP usage (h) 6.2 ± 1.9 a 4.6 ± 2.4 a 5.9 ± 1.6 a
AHI (n/h) 8.0 ± 5.6 a 4.2 ± 3.1 b 2.9 ± 3.0 c
Max pressure (cm H2O) 11.1 ± 1.4 a 10.9 ± 2.4 a 11.5 ± 3.3 a
Median pressure (cm H2O) 7.4 ± 1.3 a 7.1 ± 1.8 a 5.7 ± 1.8 b
Recommended pressure level (cm H2O) 9.9 ± 1.2 a 9.6 ± 2.0 a 9.3 ± 2.9 a
Pressure variability 2.6 ± 0.9 a 1.8 ± 0.9 b 3.0 ± 1.9 ab
For a given variable (row), columns assigned with different letters denote statistically significant difference. Conversely, for a given variable, columns 
that are sharing a same given letter are not significantly different. Mean ± SD.
Table 1: Characteristics of participating subjects.
Age (y) 49 (38 – 65)
Sex 14 M/2F
BMI (Kg/m2) 30.8 ± 4.5
ESS 12.3 ± 1.1
Co morbidities HBP (n = 6), CAD (n = 4), diabetes (n = 4), gout (n = 1), GERD (n = 1)
Medications Beta blockers (n = 4), ACE (n = 2), AR blockers (n = 2), diuretics (n = 2), nitrates (n = 2), Allopurinol (n = 1).
RDI (n/h) 38. 5 ± 20.0
ESS: Epworth Sleepiness score, RDI: respiratory disturbances index. HBP: high blood pressure, CAD: Coronary artery disease, GERD: Gastro-
oesophageal Reflux Disease, Mean (range) or SDRespiratory Research 2008, 9:56 http://respiratory-research.com/content/9/1/56
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median pressure values. This variability was significantly
lower with RemStar Auto than Autoset Spirit following the
first night and with REMStar than with the two other
devices after one-week titration (Table 2 and 3).
The mean values of recommended pressures obtained did
not significantly differ between the three machines both
after one night and one week of titration (Table 2 and 3).
However, important variations in machine-to-machine
Peff recommendations were seen (Figure 1). Significant
differences were observed in the variance of Peff recom-
mendation between the three machines after one night
(Autoset Spirit: 1.21, RemStar Auto: 3.96, GK-420: 11.37)
(p < 0.001), this difference being significant between
machine Autoset Spirit (1.42) and RemStar Auto and GK-
420 (3.45 and 7.35 respectively) after 1 week (p < 0.05).
No significant difference was found in the mean Peff val-
ues obtained after one night and one week of auto titra-
tion. However, this stability in Peff values was seen at the
expense of important increases and decreases in pressure
setting recommendations overtime (Figure 2), but with-
out systematic bias with increasing recommended pres-
sure setting. The variance of the changes in Peff overtime
significantly differed between the three machines (Autoset
Spirit: 0.4, RemStar Auto: 1.81, GK-420: 5.85) (p < 0.01).
The machine-to-machine variability in pressure setting
recommendations significantly exceeded the time-
dependent variability of this measurement.
Individual values of the recommended effective pressure (Peff) level obtained after one night and one week of automatic CPAP  titration with the three tested apparatus Figure 1
Individual values of the recommended effective pressure (Peff) level obtained after one night and one week of 
automatic CPAP titration with the three tested apparatus.
Table 3: Results of the titration studies according to each Auto CPAP device during the whole week titration.
Auto CPAP device Autoset Spirit Remstar Auto GK 420
CPAP usage (h) 5.6 ± 1.9 a 4.6 ± 1.7 a 5.0 ± 2.3 a
AHI (n/h) 7.1 ± 4.1 a 4.7 ± 3.4 b 3.1 ± 3.1 c
Max pressure (cm H2O) 10.9 ± 1.0 a 12.6 ± 2.4 b 11.0 ± 2.4 a
Median pressure (cm H2O) 7.4 ± 1.3 a 6.6 ± 1.9 a 5.9 ± 1.8 b
Recommended pressure level (cm H2O) 9.8 ± 1.1 a 9.0 ± 2.0 a 9.2 ± 2.7 a
Pressure variability 2.6 ± 0.5 a 1.8 ± 1.0 b 2.9 ± 1.6 a
Significant differences between columns are indicated by the use of different letters as described in table 2.Respiratory Research 2008, 9:56 http://respiratory-research.com/content/9/1/56
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No significant sequence and period effects were found for
any of the studied variables. The above-detailed results
were not influenced by type of recording (ambulatory or
in-lab polysomnography) used to ascertain the presence
of sleep apnea.
Discussion
Our results demonstrate that pressure behaviour signifi-
cantly differs between Auto CPAP machines both after
one night and one week of home titration. They also indi-
cate that the duration of the titration procedure does not
contribute to dampen the difference in the titration results
between the different machines. Furthermore, on an indi-
vidual basis, pressure recommendations were found to be
highly variable with time. This implies that the results of
an auto titration procedure completed with one of the
investigated device cannot be considered as similar to
those coming from a same titration protocol completed
with another auto titrating machine whatever the dura-
tion of the titration protocol. It also indicates that com-
pleting the auto titration procedure for a week does not
provide additional information to a one-night recording,
We recognize that this study has some weaknesses such as
patient selection criteria and lack of in-lab evaluation of
positive pressure requirements. As previously stated,
patients whose diagnosis was confirmed with an ambula-
tory/in-lab sleep recording had identical clinical com-
plaints, anthropometric characteristics and co-morbid
conditions. We acknowledge that the obstructive nature of
sleep-disordered breathing cannot be firmly ascertained
by the analysis of oximetry recordings [33]. However, the
absence of heart or respiratory failure in the participating
subjects, the fact that none of them was taking any CNS/
respiratory depressant medication and the ability of posi-
tive pressure therapy to abolish nocturnal breathing disor-
ders strongly support the obstructive nature of breathing
disturbances as supported by recent data published by
Mulgrew et al [34]. For these reasons, we are confident
that our results are not biased by the fact that different
types of sleep recording ascertained the presence of OSA.
A second possible drawback relates to the absence of in-
lab assessment of positive pressure needs. The aims of the
present study were to compare the pressure behaviour of
different automatic CPAP devices used in a home CPAP
titration setting. In this context, it is not possible to ascer-
tain that the effective pressure level remained unchanged
from one automatic CPAP session to the other. However,
the fact that the machine-to-machine variability in Peff
recommendation exceeded the time-dependent variabil-
ity of this variable rules out a potential effect of day-to-day
(or week-to-week) variability in positive pressure needs in
the difference in pressure recommendations between the
three machines. We are also not able to compare pressure
settings coming from automatic and manual titration
(using respectively home and in-lab titration procedures)
for each machine. Such comparison would require the
completion of an in-laboratory titration following the first
night and the one-week automatic titration procedures for
each machine. However, it is important to remember that
the tested machines were able to normalize breathing
abnormalities (or near so) in each circumstance. Consid-
ering that identification of breathing disorders and pres-
sure behaviour are intimately linked, it would be
Bland and Altman representation of the recommended effective pressure (Peff) level obtained after one night minus Peff at one  week of automatic CPAP titration against the corresponding mean Peff value for each tested apparatus Figure 2
Bland and Altman representation of the recommended effective pressure (Peff) level obtained after one night 
minus Peff at one week of automatic CPAP titration against the corresponding mean Peff value for each 
tested apparatus. (Mean ± 95% CI).Respiratory Research 2008, 9:56 http://respiratory-research.com/content/9/1/56
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interesting to have access to machines' raw data of flow/
pressure recordings and also to complete simultaneous
conventional analysis of respiratory disturbances using
sleep and ventilatory recordings during auto CPAP titra-
tion to establish the nature of breathing disorders that
drive pressure changes.
Pressure behaviour has been found to significantly differ
among Automatic CPAP machines in response to prede-
fined breathing disturbances in different bench studies
[25,26]. Our study is the first to illustrate the importance
of such behaviour on pressure setting recommendations
when these machines are used to determine an effective
pressure level at home. Recently West et al found no dif-
ference in CPAP usage, nor in the improvement in day-
time vigilance and quality of life between patients being
treated with fixed CPAP (titration being completed either
with a dedicated algorithm or with one week auto-titra-
tion procedure) or automatic CPAP [35]. However, the
effective pressure levels obtained in each group were
remarkably close, probably due to the homogeneity of the
study sample. In the present study, the range of the differ-
ence in recommended pressures was wide (-3.5 to 3.4 cm
H2O between Autoset and REMStar auto, -6.0 to 4.4 cm
H2O between Autoset and GK 420 and -2.9 to 3.4 cm H2O
between REMStar auto and GK 420). Considering that a
difference between pressure setting and effective pressure
level ≥ 1 cm H2O may interfere with treatment efficiency
[13,36], the differences in pressure behaviour that we
observed may have important clinical significance when
the recommended pressures are considered as the ones to
be set for conventional treatment with a fixed CPAP. It is
reasonable to assume that such differences in recom-
mended pressure settings may be associated with persist-
ence of residual obstructive breathing disorders and
incomplete relief of nocturnal and diurnal complaints.
The present results are particularly important when it has
been shown that there is no advantage of auto-CPAP ther-
apy compared to fixed CPAP calibrated according to an
automatic CPAP home trial [35].
The variability in Peff that we observed can theoretically
be attributed to differences in sleeping conditions and/or
in the different components of algorithm of pressure
response. There is no reason to believe that the factors
known to influence pressure setting such as body, head
and neck position and night to night variability should
differ from one home titration session to the other. There-
fore, the fact that the machine-to-machine variability in
pressure setting recommendations significantly exceeded
the time-dependent variability of this measurement
implies that the observed variability in pressure setting
relates to differences in the machines pressure responses.
Auto CPAP machines may use different signal processing
of the flow signal and different definitions of respiratory
events (hypopnea, flow limitation), may respond differ-
ently to these events (blocking in pressure rise in the
absence of improvement in flow profile, rate and amount
of pressure rise), may apply different plateauing duration
before stepping down the pressure level, and may respect
different rate and amount of pressure decrease. For exam-
ple, the response to apneic events leads to a maximal
increase in pressure of 2 cm H2O with the Autoset Spirit
but to a 1 cm H2O pressure increament/15s with the REM-
star Auto. In response to flow limitation, the respective
pressure rise is 0.3 cm H2O/breath and 0.5 cm H2O/min
for these two devices. The duration of pressure plateauing
varies between 5 breaths and 5 minutes between the three
tested machines and the range of pressure decrease goes
from 0.2 cm H2O/breath to 0.5 cm H2O/minute. As a con-
sequence of the differences in the machines algorithm of
pressure response, the variability of the applied pressure
levels was found to significantly differ between the tested
devices (recommended pressure/median pressure ratio)
despite similar mean recommended pressure values. The
present findings support the importance of machine-to-
machine differences in pressure behaviour as a contribu-
tor to the heterogeneity between CPAP levels in trials
comparing fixed and automatic CPAP therapy [37]. On
the other hand, such result implies that clinical results
obtained with one given automatic CPAP machine are
specific to the tested apparatus and cannot be applied to
other devices (i.e. to evaluate treatment benefits, to iden-
tify patients who would particularly benefit of such form
of CPAP treatment). This opens the door to a possible spe-
cificity of the usefulness of a given automatic CPAP
devices depending on the characteristics of sleep-induced
disordered breathing and of the pressure response profile
of this device. In such case, it is conceivable that patients
requiring high pressure levels could benefit of using an
auto CPAP machine different from patients who have
positional or sleep-stages dependent breathing distur-
bances.
Conclusion
There is an important variability in CPAP level recom-
mendations between automatic CPAP machines used for
home titration and that performing a prolonged titration
procedure does not reduce machine-to-machine variabil-
ity. Such differences may lead to important discrepancies
in the effective pressure level of pressure and consequently
alter CPAP compliance and/or efficiency. Considering the
impact of CPAP therapy on sleep apnea-related morbidity
and mortality and the potential benefits of automatic
CPAP titration as a cost and time effective method to ini-
tiate an effective treatment, clinical studies are needed to
better define the specificity and clinical adequacy of the
different algorithm of pressure response in determining
the effective pressure level during home titration with
automatic CPAP devices. Such studies are particularlyRespiratory Research 2008, 9:56 http://respiratory-research.com/content/9/1/56
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important to refine our ability to make a routinely ade-
quate usage of these automatic machines.
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